跳至主要内容
临床试验/NCT01944176
NCT01944176已完成3 期

The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokines in COPD Patients

Mahidol University1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2013年9月最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
24
试验地点
1
主要终点
Sputum cytokines

研究概览

简要总结

Airway inflammation is partly driven by Th17 and Th17-polarizing cytokines that is steroid-resistant. Statins could suppress IL-17 cytokines in other diseases such as atherosclerosis and multiple sclerosis in mouse model. The investigators hypothesize that statins might provide anti-inflammatory benefit of suppressing IL-17 cytokines in COPD patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
35 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Stable COPD without an exacerbation within 3 months prior to study entry
  • mild, moderate and severe COPD with or without treatments, regardless of COPD medications

排除标准

  • Concomitant other chronic lung diseases including with TB and malignancy
  • Being on immunosuppressive drugs and systemic corticosteroids
  • Dyslipidemic patients with recent cardiovascular or cerebrovascular disease within 6 month prior to study entry
  • Cognitive impairment
  • Currently on macrolides, azole anti-fungal agents, amiodarone and amlodipine

研究组 & 干预措施

Simvastatin

Experimental

simvastatin 20 mg/d is randomized to treat COPD patients for 4 weeks

干预措施: simvastatin, placebo (Drug)

B1-6-12

Placebo Comparator

B1-6-12 one tablet a day is randomized to give to COPD patients for 4 weeks

干预措施: simvastatin, placebo (Drug)

结局指标

主要结局

Sputum cytokines

时间窗: Up to 4 weeks

次要结局

  • FEV1(Up to 4 weeks)
  • Sputum neutrophils(Up to 4 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kittipong Maneechotesuwan

Professor

Mahidol University

研究点 (1)

Loading locations...

相似试验